Abstract:The antiviral endoribonuclease, RNase L, is activated by the mammalian innate immune response to destroy host and viral RNA to ultimately reduce viral gene expression. Herein, we show that RNase L and RNase L-mediated mRNA decay are primarily localized to the cytoplasm. Consequently, RNA-binding proteins (RBPs) translocate from the cytoplasm to the nucleus upon RNase L activation due to the presence of intact nuclear RNA. The re-localization of RBPs to the nucleus coincides with global alterations to RNA processing in the nucleus. While affecting many host mRNAs, these alterations are pronounced in mRNAs encoding type I and type III interferons and correlate with their retention in the nucleus and reduction in interferon protein production. Similar RNA processing defects also occur during infection with either dengue virus or SARS-CoV-2 when RNase L is activated. These findings reveal that the distribution of RBPs between the nucleus and cytosol is dictated by the availability of RNA in each compartment. Thus, viral infections that trigger RNase L-mediated cytoplasmic RNA in the cytoplasm also alter RNA processing in the nucleus, resulting in an ingenious multi-step immune block to protein biogenesis. Ribonuclease L (RNase L) initiates rapid and widespread degradation of cellular mRNAs in response to double-stranded RNA or viral infection. How the mass degradation of mRNAs affects cellular functions is unknown. Herein, we show that RNase L-mediated mRNA decay is predominately localized to the cytoplasm. Consequently, RNA-binding proteins re-localize from the cytoplasm to the nucleus upon RNase L activation. Coinciding with the influx of RNA-binding proteins into the nucleus, we also observe perturbation of nuclear processing of mRNAs, and these processing defects down-regulate key antiviral cytokines, such as type I interferons. Importantly, we observe these processes occurring during dengue virus and SARS-CoV-2 infection, revealing previously unknown aspects of antiviral gene regulation during pathogenic viral infections. Combined, these findings uncover novel mechanisms by which RNase L regulates host gene expression and expand the potential means by which RNase L blocks protein synthesis.

Endonucleolytic RNA cleavage drives changes in gene expression during the innate immune response

Initiation of a ZAKα-dependent ribotoxic stress response by the innate immunity endoribonuclease RNase L

RNase L activation in the cytoplasm induces aberrant processing of mRNAs in the nucleus

A high-resolution view of RNA endonuclease cleavage in

RNase L activates the NLRP3 inflammasome during viral infections

Z-form nucleic acid-binding protein 1 (ZBP1) as a sensor of viral and cellular Z-RNAs: walking the razor's edge

RNA dicing regulates the expression of an oncogenic JAK1 isoform

RNase-mediated reprogramming of virulence

In Vivo Cleavage Map Illuminates the Central Role of RNase E in Coding and Non-coding RNA Pathways

ZBP1/DAI ubiquitination and sensing of influenza vRNPs activate programmed cell death

Ribosome clearance during RNA interference

RNA degradome analysis reveals DNE1 endoribonuclease is required for the turnover of diverse mRNA substrates in Arabidopsis

Innate immune responses to RNA: sensing and signaling

Sensing of endogenous nucleic acids by ZBP1 induces keratinocyte necroptosis and skin inflammation

A multi-transcriptomics approach reveals the coordinated action of the endoribonuclease DNE1 and the decapping machinery in orchestrating mRNA decay

Inducible degradation of lncRNA Sros1 promotes IFN-γ-mediated activation of innate immune responses by stabilizing Stat1 mRNA

Ribonuclease activity undermines immune sensing of naked extracellular RNA

Caspase-Dependent Cleavage of DDX21 Suppresses Host Innate Immunity

Schlafen 11 triggers innate immune responses through its ribonuclease activity upon detection of single-stranded DNA

Emerging role of long noncoding RNAs as regulators of innate immune cell development and inflammatory gene expression

Triggering endogenous Z-RNA sensing for anti-tumor therapy through ZBP1-dependent necroptosis